Companies will now be in the process of assessing the impact of the industry's new agreements on their portfolio of already reimbursed medicines and even their late-stage pipelines.
Companies assess price cut impact and look ahead to April 2023
September 13, 2021 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Orthocell boosts balance sheet with capital raise to drive nerve repair product growth
October 19, 2025 - - Australian Biotech -
Amplia targets US market expansion as FAK inhibitor shows promise in pancreatic cancer
October 19, 2025 - - Australian Biotech -
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 - - Latest News -
AdvanCell unveils promising first clinical results for 212Pb-ADVC001 in prostate cancer
October 19, 2025 - - Australian Biotech -
Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access
October 18, 2025 - - Latest News -
Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer
October 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 October
October 17, 2025 - - Podcast